Cedilla is targeting processes that transition cancer-driving proteins from a stable state to a state susceptible to degradation.
Shares in Epizyme are down after a case of secondary lymphoma in one of its studies, but Jefferies expects the stock to bounce back.
Congress is debating whether to include small businesses in the Senate’s bank bill. But the SEC has an opportunity to take action on SOX 404(b) on its own.
The new angle comes from an exploratory post hoc analysis which linked the RNAi therapy to a 50% drop in hospitalization and mortality over placebo.
Eli Lilly presented a post hoc analysis of its monthly migraine therapy galcanezumab, one of a new class of targeted preventive drugs.
ZS answers the key question on medtech executives’ minds today, “How can we fund the investments required for the future while the profitability of our…
The capital will push Revolution's lead program, a SHP2 inhibitor, into the clinic.
Kenneth Berlin and Andres Gutierrez will join Advaxis as CEO and chief medical officer.
Kamada has hit another hurdle in its bid to bring the first inhaled treatment for AAT deficiency to market as an alternative to intravenous drugs.
A review revealed an imbalance in patient deaths, leading the FDA to conclude ribaxamase no longer meets the requirements for its breakthrough status.
Prothena has missed primary and secondary endpoints in its key AL amyloidosis drug NEOD001 in a midstage test.
Scripps researchers pinpointed a protein that can sense blood flow and prompt tiny blood vessels to dilate. It may be a target for drug development.